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Abstract 
Objective: To determine at two distinct time points the prevalence of resistance to ofloxacin (OFX), the representa-
tive class drug of fluoroquinolones (FQs), in M. tuberculosis isolates susceptible to first-line drugs.
Results: There were 279 M. tuberculosis isolates from the two cohorts (2004–2005: 238 isolates; 2017: 41 isolates) that 
underwent OFX drug-susceptibility testing (critical concentration: 2 µg/ml). Of 238 isolates in Cohort 1, no resistance 
to OFX was detected (95% CI 0–0.016); likewise, in Cohort 2, no resistance to OFX was detected in 41 isolates (95% CI 
0–0.086). Our findings suggest that FQ use remains a viable option for the treatment of first-line drug-susceptible TB 
in Peru.
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Introduction
Tuberculosis (TB) can be cured with effective multi-
drug therapy. However, drug intolerance or antibiotic 
resistance necessitate alternatives to current first-line 
antimicrobials [1]. Fluoroquinolones (FQ), a family of 
broad-spectrum antibiotics (ciprofloxacin (CIPRO), levo-
floxacin (LVX), moxifloxacin (MOX), ofloxacin (OFX)), 
have bactericidal activity against M. tuberculosis (Mtb) 
by inhibiting DNA gyrase, which blocks supercoiling 
and movement of replication forks [1]. Third-generation 
FQs such as LVX and MOX have greater activity against 
Mtb than earlier-generation FQs, with MOX exhibiting 
the highest activity albeit at a higher cost [1, 2]. Current 
WHO guidelines recommend the use of LVX or MOX in 
multidrug-resistant TB (MDR-TB) treatment regimens, 
as their use leads to a decreased risk of treatment failure 
or relapse, and death [3]. FQs are also used to treat drug-
susceptible TB when there is hypersensitivity or toxicity 
(especially hepatotoxicity) to first-line drugs [1, 4]. MOX 
is also part of a multidrug regimen that effectively treats 
drug-susceptible TB in 4 months [5].
FQs are widely used for diseases other than TB. In 
2002, they became the most commonly prescribed anti-
biotic class in adults in the United States [6]. Of note, 
FQs are available without prescription in several coun-
tries, including Peru [7]. A steady increase in the use 
of FQs for community-acquired respiratory infections 
may partially improve symptoms due to TB and delay 
the start of appropriate TB treatment [8]. FQ mono-
therapy can ultimately lead to FQ cross-resistance; 
DNA gyrase is the only target for FQs in Mtb, thus a 
single mutation is sufficient to cause resistance [1]. The 
rate of FQ-resistance among first-line drug-suscep-
tible has not been clearly established in Peru because 
FQ-resistance testing is not routinely performed. The 
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resistance to OFX (the representative class drug) in iso-
lates with first-line drug-susceptible M. tuberculosis at 
two distinct time points.
Main text
Materials and methods
We assessed OFX-resistance in Mtb isolates from spu-
tum samples of TB patients from San Juan de Lurigan-
cho (SJL), a TB high-burden district in Lima, Peru. 
Over 50% of TB and 60% of MDR-TB cases in Peru are 
reported in Lima, of which, SJL has among the highest 
TB incidence, reporting over 100 pulmonary TB cases 
per 100,000 inhabitants annually [9]. Second-line drug-
susceptibility testing (DST) is not routinely performed 
for first-line drug-susceptible Mtb samples. Isolates from 
first-line drug-susceptible Mtb isolates conducted in SJL 
during the periods May–August 2004 and May–August 
2005 (Cohort 1), and June-October 2017 (Cohort 2) were 
available for FQ DST. Patients were recruited prospec-
tively as part of studies to evaluate novel TB diagnostic 
methods. Patients were enrolled from their primary care 
facility prior to treatment initiation, and all provided 
written informed consent, authorizing the use of stored 
samples for future TB studies. The study was approved by 
the Institutional Ethics Committee of Universidad Peru-
ana Cayetano Heredia (SIDISI:200817) and Vanderbilt 
University Medical Center (IRB#081130).
All isolates had previously undergone DST for first-
line TB drugs performed by agar proportion method 
and underwent DST for FQs for this study. Isolates were 
cultured using BD-BBLTMMGIT™ supplemented with 
 BBLTMMGITTMOADC enrichment and confirmed as 
Mtb complex using Capilia TB-Neo. For Cohort 1, 200 µl 
of the liquid culture suspension was used to inoculate 
Löwenstein-Jensen slants. When positive, DST by agar 
proportion method using 7H10 Media was performed. 
A suspension adjusted to a McFarland standard of 1 was 
prepared and further diluted to 1:5 with distilled sterile 
water. Then 100  µl was inoculated into each quadrant. 
OFX and MOX were dissolved in 0.1 N NaOH solution 
and in sterile distilled water, respectively. Drugs were 
added to the agar plate for final concentrations: 2.0  µg/
ml for OFX and 0.5  µg/ml for MOX. For internal qual-
ity control, we used Mtb H37Rv with each new batch 
of media prepared. Additionally, a random subset of 60 
isolates was selected and sent to the TB Research Labo-
ratory at Vanderbilt University Medical Center and 
underwent repeat testing by BACTEC MGIT-960 and 
agar proportion method using the aforementioned drug 
concentrations. For cohort 2, DST by BACTEC MGIT-
960 SL-DST was performed using a drug concentration 
of 2.0 µg/ml for OFX and 1.5 µg/ml for LVX.
Results
Of 279 patients, 228 (82%) had not previously been 
treated for TB. The median age was 29  years (IQR: 
23–39), and 153 (55%) were male. There were no sig-
nificant differences in median age or male/female ratio 
between cohorts (p = 0.69 and p = 0.86, respectively). 
All Mtb isolates were susceptible to first-line drugs 
and there was no FQ-resistance detected in either 
cohort. Of 238 isolates in Cohort 1, no resistance to 
OFX or MOX was detected (95% CI 0–0.016). Like-
wise, in Cohort 2, there was no resistance to OFX or 
LVX detected in 41 isolates (95% CI 0–0.086) (Table 1). 
The 60 isolates tested at Vanderbilt University Medical 
Center were also OFX-susceptible (95% CI 0–0.06).
Discussion
Our study found no OFX-resistance in two cohorts of 
first-line drug-susceptible Mtb isolates collected 13 years 
apart. The demographic data of the participants was sim-
ilar to that of TB patients throughout Peru; almost half 
of all cases are male and young (15 to 34 years old) [9]. 
Previous studies have attempted to measure the variation 
of FQ-resistance trends over time; one study from Korea 
reported no changes in the resistance profile over 5 years, 
with an FQ-resistance average of 0.8% among non-MDR-
TB isolates, despite reported use of FQs before TB diag-
nosis [10]. Nonetheless, studies have concluded that 
prior exposure to FQs, especially in a setting where they 
can be given without prescription, is associated with FQ-
resistance [8, 11]. More than 10 days of FQ-exposure has 
been associated with a seven-fold higher risk of resist-
ance compared with non-exposure [12]. Although, FQ 
resistance rates in drug-susceptible TB are usually low 
[10, 12], caution is required since monotherapy can lead 
to resistance to not only the FQ prescribed, but also the 
entire class of FQ, limiting TB treatment options [13]. 
Also, further surveillance should be implemented to eval-
uate additional Mtb isolates and monitor for changes in 
FQ resistance rates.
Table 1 Fluoroquinolone DST among first-line drug-susceptible 
M. tuberculosis isolates
OFX: Ofloxacin; MOX: Moxifloxacin; LVX: Levofloxacin
a Cohort 1: May to August 2004 and May to August 2005
b Cohort 2: June to October 2017
Cohort  1a (n = 238) Cohort  2b (n = 41)
OFX MOX OFX LVX
Susceptible 238 238 41 41
Resistant 0 0 0 0
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FQ use prior to TB diagnosis can be as high as 
23–48% among newly-diagnosed patients [14, 15]. 
FQ-resistance is associated with worse treatment out-
comes of MDR-TB than resistance to a second-line 
injectable drug [16]. Furthermore, FQ-exposure before 
TB diagnosis is independently associated with death, 
after adjusting for age and HIV-serostatus [17]. While 
HIV infection is prevalent in less than 1% of the gen-
eral population in Peru, TB/HIV coinfection has been 
estimated to be 4.9% although higher proportions are 
found outside Lima [9].
Apart from being the best alternative for TB drug 
intolerance or resistance, FQs have promise as poten-
tial first-line treatment of drug-susceptible TB. How-
ever, FQs do not have sterilizing activity; they need to be 
given in combination with sterilizing drugs to potentially 
reduce treatment duration [2]. Results from an interna-
tional trial evaluating multi-drug treatment-shortening 
(4-month) regimens including moxifloxacin and rifap-
entine was non-inferior to standard 6-month treatment 
[5]. Treatment shortening would decrease the burden on 
the healthcare system and likely reduce the proportion of 
patients who do not complete treatment [18].
FQs remain a viable option in Peru for treating TB 
that is susceptible to first-line drugs. However, to 
ensure that this class of drugs remains a viable option 
for treatment of tuberculosis, antibiotic use should be 
regulated to limit improper, prolonged, or repeated use 
of FQs, and prevent the development of drug resistance.
Limitations
One limitation of our study is that we did not have data 
on FQ-exposure prior to TB diagnosis. The uncertainty 
regarding FQ exposure is an important factor to con-
sider as it conveys the risk of resistance and of negative 
outcomes. Resistance trends for early generation FQs 
(CIPRO) have been widely studied in Peru among gas-
trointestinal and urinary pathogens: C. jejuni (48.1%-
87.4%) and E. coli (70.4%) [19, 20]. Unfortunately, data 
are scarce on LVX or MOX use, especially for respira-
tory tract infections. Another limitation is the relatively 
small sample size, especially cohort 2. Nonetheless, the 
absence of FQ-resistance at two separate time points is 
an encouraging result given that all isolates were gath-
ered in a high-burden area with poor regulation of anti-
biotic prescriptions.
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